Clinical Trials Browser

Phase 1 × tirabrutinib × Other hematologic neoplasm × Clear all

NCT01659255 2021-03-16

Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL

Phase 1 Completed

90 enrolled 27 charts

LymphoidOther hematologic neoplasm

Lymphoma, Non-Hodgkin, Leukemia, B-Cell